BACKGROUND: Several studies have demonstrated the efficiency and safety of mild hypothermia (33 degrees C) used for treating moderate encephalopathy. In animal models, deep hypothermia proved to be neuroprotective. OBJECTIVES: To determine the safety of whole-body deep hypothermia between 30 and 33 degrees C in moderate-severe hypoxic-ischemic encephalopathy in newborn term infants. METHODS: Mortality rates, incidence of brain damage detected by magnetic resonance imaging (MRI) and neurological outcomes of 39 term asphyxiated infants were retrospectively compared. A first group of patients (control group C) was treated with routine standard methods, a second group (MH) was treated with mild whole-body hypothermia (32-34 degrees C) and a third group (DH) was treated with deep whole-body hypothermia (30-33 degrees C), for 72 h. Mean arterial pH, basic excess (BE) and lactic acid in the blood were measured. Laboratory and clinical side effects of hypothermia were investigated. A conventional brain MRI was performed after the second week of life. RESULTS: 39 term asphyxiated newborns were enrolled in the study: 11 in group C, 10 in group MH, and 18 in group DH. During the first 72 h, disseminated intravascular coagulation was recorded in 2 cases (18%) in group C, pulmonary hypertension in 2 patients (20%) in group MH, and pneumonia in 3 cases (16%) in group DH. Severe cerebral lesions and poor neurological outcome were observed in 4 cases (36%) in group C, 1 case (10%) in group MH, and 1 case (5%) in group DH. A statistically significant difference in brain damage and major clinical neurological abnormalities was observed between group C and groups MH and DH, whereas no differences were demonstrated between asphyxiated infants treated with mild or deep hypothermia. CONCLUSIONS: The results support the safety of deep hypothermia. Further studies are needed to confirm these results and the neuroprotective effect of this approach. (c) 2007 S. Karger AG, Basel.
BACKGROUND: Several studies have demonstrated the efficiency and safety of mild hypothermia (33 degrees C) used for treating moderate encephalopathy. In animal models, deep hypothermia proved to be neuroprotective. OBJECTIVES: To determine the safety of whole-body deep hypothermia between 30 and 33 degrees C in moderate-severe hypoxic-ischemicencephalopathy in newborn term infants. METHODS: Mortality rates, incidence of brain damage detected by magnetic resonance imaging (MRI) and neurological outcomes of 39 term asphyxiated infants were retrospectively compared. A first group of patients (control group C) was treated with routine standard methods, a second group (MH) was treated with mild whole-body hypothermia (32-34 degrees C) and a third group (DH) was treated with deep whole-body hypothermia (30-33 degrees C), for 72 h. Mean arterial pH, basic excess (BE) and lactic acid in the blood were measured. Laboratory and clinical side effects of hypothermia were investigated. A conventional brain MRI was performed after the second week of life. RESULTS: 39 term asphyxiated newborns were enrolled in the study: 11 in group C, 10 in group MH, and 18 in group DH. During the first 72 h, disseminated intravascular coagulation was recorded in 2 cases (18%) in group C, pulmonary hypertension in 2 patients (20%) in group MH, and pneumonia in 3 cases (16%) in group DH. Severe cerebral lesions and poor neurological outcome were observed in 4 cases (36%) in group C, 1 case (10%) in group MH, and 1 case (5%) in group DH. A statistically significant difference in brain damage and major clinical neurological abnormalities was observed between group C and groups MH and DH, whereas no differences were demonstrated between asphyxiated infants treated with mild or deep hypothermia. CONCLUSIONS: The results support the safety of deep hypothermia. Further studies are needed to confirm these results and the neuroprotective effect of this approach. (c) 2007 S. Karger AG, Basel.
Authors: Kristin Guilliams; Max Rosen; Sandra Buttram; John Zempel; Jose Pineda; Barbara Miller; Michael Shoykhet Journal: Epilepsia Date: 2013-08-01 Impact factor: 5.864
Authors: Susan E Jacobs; Marie Berg; Rod Hunt; William O Tarnow-Mordi; Terrie E Inder; Peter G Davis Journal: Cochrane Database Syst Rev Date: 2013-01-31
Authors: Seetha Shankaran; Abbot R Laptook; Athina Pappas; Scott A McDonald; Abhik Das; Jon E Tyson; Brenda B Poindexter; Kurt Schibler; Edward F Bell; Roy J Heyne; Claudia Pedroza; Rebecca Bara; Krisa P Van Meurs; Cathy Grisby; Carolyn M Petrie Huitema; Meena Garg; Richard A Ehrenkranz; Edward G Shepherd; Lina F Chalak; Shannon E G Hamrick; Amir M Khan; Anne Marie Reynolds; Matthew M Laughon; William E Truog; Kevin C Dysart; Waldemar A Carlo; Michele C Walsh; Kristi L Watterberg; Rosemary D Higgins Journal: JAMA Date: 2014 Dec 24-31 Impact factor: 56.272
Authors: Jia Liu; Lawrence Litt; Mark R Segal; Mark J S Kelly; Hikari A I Yoshihara; Thomas L James Journal: J Cereb Blood Flow Metab Date: 2010-08-18 Impact factor: 6.200
Authors: Aron Kerenyi; Dorottya Kelen; Stuart D Faulkner; Alan Bainbridge; Manigandan Chandrasekaran; Ernest B Cady; Xavier Golay; Nicola J Robertson Journal: Pediatr Res Date: 2012-02-07 Impact factor: 3.756